Physician profile
David C Preston
NPI 1316965791
$6,239.40
in general payments reported to CMS, 2019-2025
28 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,098 · 2020: $149 · 2021: $275 · 2022: $401 · 2023: $430 · 2024: $1,872 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816 · Honoraria: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.86 |
| Honoraria | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Natus Medical Incorporated | $1,516.35 | 2021-2024 | |
| Nihon Kohden America, LLC | $1,500.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $859.90 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $461.38 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $402.63 | 2019-2025 | Zilbrysq |
| Genentech USA, INC. | $199.21 | 2019-2025 | Ocrevus, Enspryng |
| Genzyme Corporation | $188.36 | 2019-2023 | |
| Amgen INC. | $146.43 | 2019-2025 | Uplizna |
| Csl Behring | $113.34 | 2019-2022 | |
| Allergan, INC. | $102.59 | 2021-2022 | |
| Lundbeck LLC | $101.59 | 2019-2025 | Vyepti |
| Jazz Pharmaceuticals INC. | $89.70 | 2024 | |
| Portola Pharmaceuticals, LLC | $70.94 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.23 | 2023-2025 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $53.88 | 2019-2025 | Austedo Xr, Austedo Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $41.45 | 2025 | Onpattro |
| Tg Therapeutics, INC. | $37.22 | 2025 | |
| Abbvie INC. | $37.11 | 2023-2025 | |
| Lilly USA, LLC | $36.33 | 2023-2024 | Reyvow, Emgality |
| Horizon Therapeutics Plc | $35.16 | 2022 | |
| Pfizer INC. | $30.10 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $29.92 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.51 | 2022 | |
| Averitas Pharma INC. | $26.47 | 2025 | Qutenza |
| Sk Life Science, INC. | $18.95 | 2025 | |
| Supernus Pharmaceuticals, INC. | $15.61 | 2020 | |
| Novartis Pharmaceuticals Corporation | $15.25 | 2023 | |
| Avanir Pharmaceuticals, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Preston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.